Novel technique for characterizing prostate cancer utilizing MRI restriction spectrum imaging: Proof of principle and initial clinical experience with extraprostatic extension - Abstract

BACKGROUND: Standard magnetic resonance imaging (MRI) of the prostate lacks sensitivity in the diagnosis and staging of prostate cancer (PCa).

To improve the operating characteristics of prostate MRI in the detection and characterization of PCa, we developed a novel, enhanced MRI diffusion technique using restriction spectrum imaging (RSI-MRI).

METHODS: We compared the efficacy of our novel RSI-MRI technique with standard MRI for detecting extraprostatic extension (EPE) among 28 PCa patients who underwent MRI and RSI-MRI prior to radical prostatectomy, 10 with histologically proven pT3 disease. RSI cellularity maps isolating the restricted isotropic water fraction were reconstructed based on all b-values and then standardized across the sample with z-score maps. Distortion correction of the RSI maps was performed using the alternating phase-encode technique.

RESULTS: 27 Patients were evaluated, excluding one patient where distortion could not be performed. Preoperative standard MRI correctly identified extraprostatic the extension in two of the nine pT3 (22%) patients, whereas RSI-MRI identified EPE in eight of nine (89%) patients. RSI-MRI correctly identified pT2 disease in the remaining 18 patients.

CONCLUSIONS: In this proof of principle study, we conclude that our novel RSI-MRI technology is feasible and shows promise for substantially improving PCa imaging. Further translational studies of prostate RSI-MRI in the diagnosis and staging of PCa are indicated.

Written by:
Rakow-Penner RA, White NS, Parsons JK, Choi HW, Liss MA, Kuperman JM, Schenker-Ahmed N, Bartsch H, Mattrey RF, Bradley WG, Shabaik A, Huang J, Margolis DJ, Raman SS, Marks L, Kane CJ, Reiter RE, Karow DS, Dale AM.   Are you the author?
Department of Radiology, School of Medicine, University of California San Diego, La Jolla, CA, USA; Department of Urology, School of Medicine, University of California San Diego, La Jolla, CA, USA; Department of Pathology, School of Medicine, University of California San Diego, La Jolla, CA, USA; Department of Pathology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA; Department of Radiology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA; Department of Urology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.

Reference: Prostate Cancer Prostatic Dis. 2015 Mar;18(1):81-5.
doi: 10.1038/pcan.2014.50


PubMed Abstract
PMID: 25559097

UroToday.com Prostate Cancer Section

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe